COMPANY
Camurus AB
Camurus AB: marketing authorisation holder, trial sponsor for Octreotide, Lanreotide, Leuprolide, Semaglutide, as stated by public registers.
Also written as: CAMURUS AB.
MARKETING AUTHORISATION HOLDER
Holds the licence to sell the medicine in a country (EMA, MHRA, Health Canada).
| Octreotide | Oczyesa (EMEA/H/C/006322), Authorised Regulator EMA |
|---|---|
| Octreotide | OCZYESA 20 MG PROLONGED-RELEASE SOLUTION FOR INJECTION IN PRE-FILLED PEN, PL 42800/0011, Authorised Regulator MHRA |
TRIAL SPONSOR
Sponsors registered clinical trials of the peptide.
| Lanreotide | 1 registered trial Trial register EU CTIS |
|---|---|
| Lanreotide | 1 registered trial Trial register ClinicalTrials.gov |
| Leuprolide | 1 registered trial Trial register ClinicalTrials.gov |
| Octreotide | 3 registered trials Trial register EU CTIS |
| Octreotide | 6 registered trials Trial register ClinicalTrials.gov |
| Semaglutide | 2 registered trials Trial register EU CTIS |
What a register states, not an endorsement or an accusation by this site. All companies.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.